Moody's Ratings (Moody's) has upgraded Global Partners LP's (Global) Corporate Family Rating (CFR) to Ba3 from B1, Probability of Default Rating (PDR) to Ba3-PD from B1-PD, and senior unsecured notes ratings to B1 from B2. The Speculative Grade Liquidity (SGL) rating was upgraded to SGL-2 from SGL-3...
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177Lu-DOTAIncreased tumor retention and total tumor uptake anticipated by using optimized universal RadiohaptenCompany plans to initiate a Trial 1001 Bridge study (Part 2A) with optimized Radiohapten, “Proteus”, in 1H 2026 with data readout in 2H...
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of GD2-SADA in recurrent or refractory metastatic solid tumors known to express GD2 in a trial in progress poster at the Advances in Neuroblastoma...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.